| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt.
|
Cancer Res
|
2006
|
18.44
|
|
2
|
Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy.
|
Proc Natl Acad Sci U S A
|
2010
|
3.16
|
|
3
|
A fully human monoclonal antibody to the insulin-like growth factor I receptor blocks ligand-dependent signaling and inhibits human tumor growth in vivo.
|
Cancer Res
|
2003
|
3.09
|
|
4
|
IMC-A12, a human IgG1 monoclonal antibody to the insulin-like growth factor I receptor.
|
Clin Cancer Res
|
2007
|
1.87
|
|
5
|
In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors.
|
Clin Cancer Res
|
2005
|
1.82
|
|
6
|
Therapeutic implications of a human neutralizing antibody to the macrophage-stimulating protein receptor tyrosine kinase (RON), a c-MET family member.
|
Cancer Res
|
2006
|
1.52
|
|
7
|
Combined in vivo effect of A12, a type 1 insulin-like growth factor receptor antibody, and docetaxel against prostate cancer tumors.
|
Clin Cancer Res
|
2006
|
1.47
|
|
8
|
Anti-vascular endothelial growth factor receptor-1 antagonist antibody as a therapeutic agent for cancer.
|
Clin Cancer Res
|
2006
|
1.46
|
|
9
|
A fully human recombinant IgG-like bispecific antibody to both the epidermal growth factor receptor and the insulin-like growth factor receptor for enhanced antitumor activity.
|
J Biol Chem
|
2005
|
1.41
|
|
10
|
Anti-transforming growth factor beta receptor II antibody has therapeutic efficacy against primary tumor growth and metastasis through multieffects on cancer, stroma, and immune cells.
|
Clin Cancer Res
|
2010
|
1.28
|
|
11
|
Insulin-like growth factor-I receptor signaling blockade combined with radiation.
|
Cancer Res
|
2007
|
1.24
|
|
12
|
IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab.
|
Hum Antibodies
|
2010
|
1.16
|
|
13
|
Antibody targeting of the insulin-like growth factor I receptor enhances the anti-tumor response of multiple myeloma to chemotherapy through inhibition of tumor proliferation and angiogenesis.
|
Cancer Immunol Immunother
|
2006
|
1.15
|
|
14
|
DEGA/AMIGO-2, a leucine-rich repeat family member, differentially expressed in human gastric adenocarcinoma: effects on ploidy, chromosomal stability, cell adhesion/migration and tumorigenicity.
|
Oncogene
|
2004
|
1.14
|
|
15
|
Targeting the platelet-derived growth factor receptor alpha with a neutralizing human monoclonal antibody inhibits the growth of tumor xenografts: implications as a potential therapeutic target.
|
Mol Cancer Ther
|
2005
|
1.09
|
|
16
|
Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2.
|
Biochem Biophys Res Commun
|
2006
|
1.08
|
|
17
|
An antibody targeting the type I insulin-like growth factor receptor enhances the castration-induced response in androgen-dependent prostate cancer.
|
Clin Cancer Res
|
2007
|
1.01
|
|
18
|
Selective inhibition of SCLC growth by the A12 anti-IGF-1R monoclonal antibody correlates with inhibition of Akt.
|
Lung Cancer
|
2007
|
1.01
|
|
19
|
Inhibitory anti-FLT3 antibodies are capable of mediating antibody-dependent cell-mediated cytotoxicity and reducing engraftment of acute myelogenous leukemia blasts in nonobese diabetic/severe combined immunodeficient mice.
|
Cancer Res
|
2005
|
1.00
|
|
20
|
Development of a fully human anti-PDGFRbeta antibody that suppresses growth of human tumor xenografts and enhances antitumor activity of an anti-VEGFR2 antibody.
|
Neoplasia
|
2009
|
0.99
|
|
21
|
Insulin-like growth factor type 1 receptor and insulin receptor isoform expression and signaling in mammary epithelial cells.
|
Endocrinology
|
2009
|
0.98
|
|
22
|
Blockade of insulin-like growth factor type-1 receptor with cixutumumab (IMC-A12): a novel approach to treatment for multiple cancers.
|
Curr Drug Targets
|
2011
|
0.97
|
|
23
|
An antibody directed against PDGF receptor beta enhances the antitumor and the anti-angiogenic activities of an anti-VEGF receptor 2 antibody.
|
Biochem Biophys Res Commun
|
2007
|
0.93
|
|
24
|
Single variable domain antibody as a versatile building block for the construction of IgG-like bispecific antibodies.
|
J Immunol Methods
|
2006
|
0.92
|
|
25
|
Insulin-like growth factor-I receptor (IGF-IR) targeting with monoclonal antibody cixutumumab (IMC-A12) inhibits IGF-I action in endometrial cancer cells.
|
Eur J Cancer
|
2011
|
0.91
|
|
26
|
Dual inhibition of epidermal growth factor receptor and insulin-like growth factor receptor I: reduction of angiogenesis and tumor growth in cutaneous squamous cell carcinoma.
|
Head Neck
|
2011
|
0.89
|
|
27
|
Suppression of leukemia expressing wild-type or ITD-mutant FLT3 receptor by a fully human anti-FLT3 neutralizing antibody.
|
Blood
|
2004
|
0.87
|
|
28
|
A universal combinatorial design of antibody framework to graft distinct CDR sequences: a bioinformatics approach.
|
Proteins
|
2011
|
0.84
|
|
29
|
Transforming Growth Factor-{beta}-Stimulated Clone-22 Is an Androgen-Regulated Gene That Enhances Apoptosis in Prostate Cancer following Insulin-Like Growth Factor-I Receptor Inhibition.
|
Clin Cancer Res
|
2009
|
0.83
|
|
30
|
Development of a novel and efficient cell culture flocculation process using a stimulus responsive polymer to streamline antibody purification processes.
|
Biotechnol Bioeng
|
2013
|
0.83
|
|
31
|
Generation and characterization of a therapeutic human antibody to melanoma antigen TYRP1.
|
Hum Antibodies
|
2007
|
0.83
|
|
32
|
Prioritization of EGFR/IGF-IR/VEGFR2 combination targeted therapies utilizing cancer models.
|
Anticancer Res
|
2009
|
0.78
|
|
33
|
A bi-functional antibody-receptor domain fusion protein simultaneously targeting IGF-IR and VEGF for degradation.
|
MAbs
|
2015
|
0.78
|